LOS ANGELES, July 10, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the Company will deliver a presentation at Viruses of Microbes 2024, which is being held July 15-19, 2024, in Cairns, Australia.
Details of the presentation are as follows:
Title: | Advancing Bacteriophage Therapy from Discovery to Clinical Trials |
Session: | Phage Therapy Session 2 – Clinical Application |
Presenter: | Steven Branston, Australia Site Head |
Day: | Thursday, July 18 |
Time: | 11:20am-11:40am AEST (9:20pm-9:40pm EDT on Wednesday, July 17) |
For more information: https://www.vom2024.org/ | |
Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage specific cGMP manufacturing.
At Armata:
Pierre Kyme
Armata Pharmaceuticals, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
310-665-2928
Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.
212-915-2569
| Last Trade: | US$2.40 |
| Daily Change: | -0.02 -0.83 |
| Daily Volume: | 6,900 |
| Market Cap: | US$86.860M |
May 14, 2025 March 20, 2025 March 11, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
